The Mayo Test: Impact On Personalized Medicine And Beyond
April 25, 2012, 1:36 PM EDT
Law360, New York (April 25, 2012, 1:36 PM EDT) -- With a unanimous decision issued on March 20, 2012, in Mayo v. Prometheus Laboratories, the U.S. Supreme Court invalidated the process claims of Prometheus’ two patents as not patent-eligible based on the finding that the steps in the claimed processes apart from the natural law inherent in the definition of the invention “involve [only] well-understood, routine, conventional activity previously engaged in by researchers in the field.”
This decision reversed the Federal Circuit’s finding of patent eligibility based on the “machine or transformation” test. While acknowledging the...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.